BioCryst Pharmaceuticals Förvaltning
Förvaltning kriterier kontrolleras 1/4
BioCryst Pharmaceuticals VD är Charlie Gayer, utsedd i Aug 2025, har en mandatperiod på mindre än ett år. totala årliga ersättningen är $ 9.63M, bestående av 6.3% lön 93.7% bonusar, inklusive företagsaktier och optioner. äger direkt 0.14% av företagets aktier, värda $ 3.03M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 0.8 år respektive 4.7 år.
Viktig information
Charlie Gayer
Verkställande direktör
US$9.6m
Total ersättning
| VD-lön i procent | 6.33% |
| Anställning som VD | less than a year |
| Ägande av VD | 0.1% |
| Ledningens genomsnittliga anställningstid | less than a year |
| Styrelsens genomsnittliga mandatperiod | 4.7yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • May 16
BCRX: Astria Integration And Licensing Deal Will Support Hereditary Angioedema Expansion
Analysts have nudged their average price target on BioCryst higher by low single digits in recent weeks, citing reiterated long-term revenue goals following the Astria Therapeutics acquisition, ongoing confidence in Orladeyo and navenibart sales potential, and steadier expectations for future profitability and P/E levels. Analyst Commentary Recent research has leaned constructive on BioCryst, with several bullish analysts adjusting their price targets upward and reaffirming confidence in the company’s long term revenue framework following the Astria Therapeutics acquisition.
Uppdatering av berättelse • May 01
BCRX: Astria Deal And FY26 Goals Will Support Rare Disease Upside
Analysts have inched their average price target on BioCryst Pharmaceuticals higher by $0.10 to $21.40, reflecting research that points to steady commercial execution, reiterated long term revenue goals following the Astria Therapeutics acquisition, and continued interest in the BCX17725 program as well as Orladeyo and navenibart sales potential. Analyst Commentary Recent research highlights a mix of enthusiasm and caution around BioCryst, with price targets edging higher and coverage resuming as analysts digest the Astria Therapeutics acquisition, updated guidance, and the company’s rare disease portfolio.Uppdatering av berättelse • Apr 17
BCRX: Astria Integration And 2031 Debt Structure Will Support Hereditary Angioedema Expansion
Narrative Update Analysts have nudged their price targets on BioCryst Pharmaceuticals higher by $1. This reflects continued confidence in management's reiterated FY26 guidance, the integration of the Astria Therapeutics acquisition, and the longer term potential they see in Orladeyo and navenibart.Uppdatering av berättelse • Apr 03
BCRX: Astria Acquisition And FY26 Guidance Will Support Long-Term Revenue Potential
Analysts lifted their price target on BioCryst Pharmaceuticals to $22 from $21, citing steady forward guidance, reaffirmed peak revenue goals following the Astria Therapeutics acquisition, and confidence in Orladeyo and the BCX17725 program as key factors supporting the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as supported by reiterated FY26 guidance and peak revenue goals, which they view as evidence that management is confident in the current growth plan.
Uppdatering av berättelse • Mar 20
BCRX: Astria Acquisition And FY26 Outlook Will Support Long Term Upside
Analysts lifted their price targets on BioCryst to a range of $17 to $22, citing steady FY26 guidance, reaffirmed peak revenue goals, and confidence in the Astria Therapeutics acquisition and BCX17725 data timeline as key supports for the higher valuations. Analyst Commentary Recent Street research on BioCryst highlights a mix of optimism around the Astria Therapeutics acquisition, reaffirmed FY26 guidance, and the commercial trajectory of Orladeyo, alongside growing interest in the BCX17725 program as a potential long term driver.Seeking Alpha • Mar 17
BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real
Summary BioCryst Pharmaceuticals remains a cash-generative orphan drug player, with ORLADEYO as its mature but still growing lead asset. Despite recent buyout rumors, I view a takeout as speculative and maintain a 'Hold' rating until more definitive catalysts emerge. ORLADEYO's future growth is challenged by new high-efficacy HAE treatments, while navenibart's Phase 3 data (expected 2027) could redefine BCRX's outlook. Financially, BCRX preserved liquidity post-Astria acquisition, guiding FY26 revenues of $625M–$645M and outpacing non-GAAP opex. Read the full article on Seeking AlphaUppdatering av berättelse • Mar 05
BCRX: Astria Acquisition And FY26 Outlook Will Support Long-Term HAE Leadership
Analysts have raised their blended price target on BioCryst Pharmaceuticals to about $21.30 from $20.50, citing reaffirmed FY26 guidance, reiterated peak revenue goals after the Astria Therapeutics acquisition, and continued confidence in the commercial ramp and the BCX17725 data timeline. Analyst Commentary Bullish Takeaways Bullish analysts see the higher blended price targets, up to about $22, as reflecting confidence in execution on the FY26 guidance and the longer term revenue framework.Uppdatering av berättelse • Feb 19
BCRX: Astria Acquisition Will Drive Hereditary Angioedema Franchise Expansion
Analysts have reaffirmed their $32.00 fair value estimate for BioCryst Pharmaceuticals and supported a $17.00 price target, citing expectations for Orladeyo to potentially reach $900m in sales by 2029 and for navenibart to approach $1b in risk adjusted sales following the Astria Therapeutics acquisition. Analyst Commentary Bullish analysts view the reaffirmed US$32.00 fair value estimate and the US$17.00 price target as grounded in a clearer revenue roadmap, with both Orladeyo and navenibart framed as key building blocks of the story rather than optional upside.Uppdatering av berättelse • Feb 05
BCRX: Pediatric Approval And 2031 Financing Will Strengthen Long Term Outlook
Narrative Update Overview Analysts have raised their price target on BioCryst Pharmaceuticals from US$11.00 to US$13.00, reflecting updated assumptions on revenue, profit margins, discount rate and future P/E multiples in their valuation work. What's in the News Entered a new loan agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. for term loans with gross proceeds of US$400 million, issued in multiple tranches and maturing on January 23, 2031, with quarterly interest-only payments and principal due at maturity (company announcement).Uppdatering av berättelse • Jan 22
BCRX: Pediatric Expansion And 2025 Profitability Outlook Will Support Long-Term HAE Leadership
Narrative Update Overview Analysts now see fair value for BioCryst Pharmaceuticals at US$20.50 per share, a US$0.10 adjustment that reflects updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News BioCryst issued full year 2026 earnings guidance, with total revenue expected in a range of US$635 million to US$660 million (company guidance).Uppdatering av berättelse • Jan 08
BCRX: Astria Acquisition Will Extend HAE Leadership With Long Acting Injectable Through 2042
Narrative Update: BioCryst Pharmaceuticals The updated analyst price target for BioCryst Pharmaceuticals has moved modestly higher to about $20.60 from $20.40, with analysts pointing to the planned $700m acquisition of Astria Therapeutics, expected SG&A synergies, and the potential of HAE candidate navenibart to support BioCryst's hereditary angioedema franchise as key reasons for their revised view. Analyst Commentary Street research around BioCryst's planned US$700m acquisition of Astria Therapeutics clusters around the same core themes, but with different levels of enthusiasm about execution risk, competitive pressure, and valuation.Uppdatering av berättelse • Dec 24
BCRX: Astria Acquisition Will Extend Hereditary Angioedema Leadership Through Navenibart
We raise our BioCryst Pharmaceuticals fair value estimate to $32.00 from $28.15, as analysts highlight the accretive $700M Astria Therapeutics acquisition and its potential to extend the company’s hereditary angioedema leadership with long acting navenibart through the next decade. Analyst Commentary Analysts with a positive view on the stock are broadly endorsing BioCryst's acquisition of Astria Therapeutics, describing it as a value-accretive move that enhances the company’s hereditary angioedema portfolio and extends its potential growth runway into the 2030s and beyond.Uppdatering av berättelse • Dec 10
BCRX: Astria Acquisition Will Extend HAE Leadership With Long-Acting Injectable Through 2042
Analysts have lifted their average price targets on BioCryst Pharmaceuticals by a mid-teens dollar amount into the mid to high $20s per share range, citing the proposed $700M acquisition of Astria Therapeutics as a strategically sound, earnings-accretive move that extends the company’s hereditary angioedema leadership and reduces long-term growth risk. Analyst Commentary Street research following the Astria Therapeutics deal skews constructive, with most price target revisions reflecting higher confidence in BioCryst’s long term growth profile and durability in hereditary angioedema, even as investors weigh near term dilution and competitive risks.Uppdatering av berättelse • Nov 26
BCRX: Acquisition Will Extend HAE Franchise With New Long-Acting Candidate Through 2042
BioCryst Pharmaceuticals’ fair value estimate has increased from $19.73 to $20.40 per share. Analysts cite the company’s acquisition of Astria Therapeutics and improved long-term growth prospects following recent price target raises by multiple firms.Uppdatering av berättelse • Nov 12
BCRX: Acquisition Will Drive Earnings Upside With New HAE Candidate Through 2042
BioCryst Pharmaceuticals' fair value estimate has been adjusted downward by approximately $0.55 per share, as analysts incorporate the strategic rationale and expected synergies following the announced acquisition of Astria Therapeutics. Analyst Commentary Market observers have provided a range of insights following BioCryst Pharmaceuticals' acquisition of Astria Therapeutics.Analysartikel • Nov 06
Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Last week saw the newest third-quarter earnings release from BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ), an...Uppdatering av berättelse • Oct 29
Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion
Analysts have raised their price target for BioCryst Pharmaceuticals from $18.50 to approximately $20.27 per share. This change reflects optimism about the company's acquisition of Astria Therapeutics and its anticipated impact on future growth and market position.Uppdatering av berättelse • Oct 14
Expanding Rare Disease Pipeline Will Open New Markets
Analysts have raised their fair value estimate for BioCryst Pharmaceuticals to $18.50 from $16.73. They cited the anticipated long-term benefits and strategic alignment from the recent Astria Therapeutics acquisition, despite some near-term uncertainties.Analysartikel • Aug 07
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
A week ago, BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) came out with a strong set of quarterly numbers that could...Ny berättelse • May 09
ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities
ORLADEYO's revenue growth, patient conversion, and reduced royalty payments enhance profitability, cash flow, and financial stability for BioCryst Pharmaceuticals.Seeking Alpha • Feb 25
BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
Summary I initially rated BioCryst a "Sell" in November 2023, but am now upgrading to "Hold" as the company has outperformed my expectations, despite competitive pressures. Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition and may not reach management's $1bn annual revenue target in my view. Q4 2024 earnings showed a notable improvement with a reduced GAAP operating loss and a positive non-GAAP operating profit, but guidance for ~22% growth led to a sell-off. Despite promising near-term growth and potential label expansions, long-term risks and reliance on Orladeyo remain concerns, making the stock fairly valued at this time in my view. Read the full article on Seeking AlphaAnalysartikel • Feb 15
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Fly 25% But Investors Aren't Buying For Growth
The BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) share price has done very well over the last month, posting an...Seeking Alpha • Dec 09
BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
Summary BioCryst remains a "Buy" due to ORLADEYO's proven success, potential growth, and management's confidence despite significant competition and a one-dimensional revenue stream. Q3 2024 showed mixed results with a modest revenue beat and slight earnings miss, leading to a 13% stock drop on higher volume. ORLADEYO's revenue guidance is strong, with expectations of reaching $1 billion annually by 2029, driven by its convenience and efficacy. BioCryst's financial health is solid with positive cash flow in Q3, a strong cash position, and no immediate need for additional capital. Read the full article on Seeking AlphaSeeking Alpha • Sep 29
BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)
Summary BioCryst's Q2 earnings exceeded expectations, with Orladeyo revenues driving a 34% YoY growth, signaling a faster path to profitability. Despite fierce competition, Orladeyo's market performance and international expansion bolster confidence in its potential to reach $1 billion in annual revenue. BioCryst's financial health is solid, with a current ratio above 2 and a cash runway of approximately 2.5 years, aiming for positive cash flow by late 2025. Upgrading BioCryst to a "hold" rating due to improved financials and Orladeyo's growth, but caution remains due to competition and potential R&D setbacks. Read the full article on Seeking AlphaAnalys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$458m |
| Dec 31 2025 | US$10m | US$609k | US$264m |
| Sep 30 2025 | n/a | n/a | -US$9m |
| Jun 30 2025 | n/a | n/a | -US$36m |
| Mar 31 2025 | n/a | n/a | -US$53m |
| Dec 31 2024 | US$3m | US$545k | -US$89m |
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$146m |
| Mar 31 2024 | n/a | n/a | -US$209m |
| Dec 31 2023 | US$2m | US$495k | -US$227m |
| Sep 30 2023 | n/a | n/a | -US$236m |
| Jun 30 2023 | n/a | n/a | -US$243m |
| Mar 31 2023 | n/a | n/a | -US$226m |
| Dec 31 2022 | US$2m | US$449k | -US$247m |
Ersättning vs marknad: Charlie s total kompensation ($USD 9.63M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 5.45M ).
Ersättning vs inkomst: Ersättningen för Charlie har ökat samtidigt som företaget är olönsamt.
VD OCH KONCERNCHEF
Charlie Gayer (54 yo)
less than a year
Anställning
US$9,627,868
Kompensation
Mr. Charles K. Gayer, also known as Charlie, is President at BioCryst Pharmaceuticals, Inc. since August 1, 2025 and serves as its CEO & Director since January 01, 2026. He served as the Senior Vice Presid...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$9.63m | 0.14% $ 3.0m | |
| CFO & Head of Corporate Development | less than a year | US$6.75m | inga uppgifter | |
| Senior VP | 19.7yrs | US$5.62m | 0.058% $ 1.2m | |
| Chief Technical Operations Officer | less than a year | inga uppgifter | inga uppgifter | |
| Manager of Investor Relations | no data | inga uppgifter | inga uppgifter | |
| Chief People Officer & Chief Communications Officer | less than a year | inga uppgifter | inga uppgifter | |
| Chief Development Officer | 17.8yrs | US$2.66m | inga uppgifter | |
| Chief Discovery Officer | 12.6yrs | US$2.57m | inga uppgifter | |
| Chief Data Innovation Officer | 4.5yrs | inga uppgifter | inga uppgifter | |
| Chief Strategy Officer | 3.7yrs | inga uppgifter | inga uppgifter | |
| Chief Commercial Officer | less than a year | inga uppgifter | 0.020% $ 431.6k | |
| Chief Research & Development Officer | less than a year | inga uppgifter | inga uppgifter |
0.8yrs
Genomsnittlig anställningstid
59yo
Genomsnittlig ålder
Erfaren ledning: BCRX s ledningsgrupp anses inte vara erfaren ( 0.8 års genomsnittlig anställningstid), vilket föreslår ett nytt team.
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$9.63m | 0.14% $ 3.0m | |
| Independent Chairman | 4.8yrs | US$403.70k | 0.031% $ 666.1k | |
| Independent Director | 6.3yrs | US$397.50k | 0.020% $ 433.3k | |
| Independent Director | 1yr | US$396.49k | 0.0018% $ 38.1k | |
| Independent Director | less than a year | inga uppgifter | 0.0060% $ 128.7k | |
| Independent Director | 7.4yrs | US$401.70k | 0.021% $ 442.3k | |
| Director | 19.3yrs | US$12.95m | 0.41% $ 8.7m | |
| Independent Director | 4.7yrs | US$385.58k | 0.023% $ 488.7k | |
| Independent Director | 4.3yrs | US$385.25k | 0.0071% $ 151.9k | |
| Independent Director | 4.7yrs | US$390.00k | 0.012% $ 250.6k |
4.7yrs
Genomsnittlig anställningstid
62yo
Genomsnittlig ålder
Erfaren styrelse: BCRX s styrelse anses vara erfaren ( 4.7 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/22 03:59 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
BioCryst Pharmaceuticals, Inc. bevakas av 27 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |